Company Overview of Lycera Corp.
Lycera Corp., a biopharmaceutical company, discovers and develops oral immune modulators for the treatment of patients with autoimmune diseases and cancers. Its product pipeline includes LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease; oral RORgamma agonists for diverse applications in immune-oncology; and Rho kinase inhibitors, histone deacetylase 6 inhibitors, RORgt antagonists, and collaboration targets. Lycera Corp. was founded in 2006 and is headquartered in Ann Arbor, Michigan.
2800 Plymouth Road
Ann Arbor, MI 48109
Founded in 2006
Key Executives for Lycera Corp.
Chief Executive Officer, President and Director
Co-Founder, Chief Scientific Officer and Director
Senior Vice President of Biology
Compensation as of Fiscal Year 2015.
Lycera Corp. Key Developments
Lycera Corp. Enters into License Agreement with Celgene Corporation
Jan 11 16
Lycera Corp. announced that it entered into a license agreement with its collaboration partner Celgene Corporation. Under the agreement, Lycera granted to Celgene an exclusive license for Lycera's portfolio of novel ex vivo RORgamma agonist compounds. Lycera is the leader in discovering and developing selective and potent oral agonists that target RORgamma, a master control switch of immune system activation, for the potential treatment of a broad range of cancers. While Lycera has developed orally bioavailable RORgamma agonists that have demonstrated single agent therapeutic activity in multiple animal models of cancer, ex vivo treatment with RORgamma agonist compounds has been shown to enhance the therapeutic benefit of adoptive T-cell therapy by improving both immune cell persistence and activation. Under the terms of the license agreement, Lycera received a $17.5 million upfront cash payment and has the potential to receive an additional near-term milestone payment of $5 million. In June 2015, Lycera and Celgene entered an exclusive global collaboration to take forward Lycera's proprietary product development pipeline for cancer and immune-mediated diseases. Key programs being advanced under this collaboration include LYC-30937 EC and Lycera's RORgamma agonists, as well as earlier-stage programs including a Rho-associated protein kinase 2 (ROCK2) inhibitor. As part of the strategic collaboration agreement, Celgene obtained the exclusive right to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones. During the option period, Lycera retains full control of its research and development programs. Following the exercise of the option to acquire Lycera, shareholders will also be eligible to receive future success-based milestones.
Lycera Corp. Presents at Boston Biotech East West CEO Conference, Jan-09-2016 09:55 AM
Jan 1 16
Lycera Corp. Presents at Boston Biotech East West CEO Conference, Jan-09-2016 09:55 AM. Venue: Four Seasons Hotel, 757 Market St., San Francisco, CA 94103, United States. Speakers: Paul J. Sekhri, Chief Executive Officer, President and Director.
Lycera Corp. Presents at Boston Biotech Conferences 2015, Nov-12-2015 02:00 PM
Nov 8 15
Lycera Corp. Presents at Boston Biotech Conferences 2015, Nov-12-2015 02:00 PM. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 12, 2015